Biopharmaceuticals Exploring RNA Therapy Alnylam Pharmaceuticals (Nasdaq: ALNY) Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Arbutus Biopharma (Nasdaq: ABUS) Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company primarily dedicated to discovering, developing, and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated drug discovery and ...